MGNX – Macrogenics Inc
MacroGenics, Inc.MGNX
$1.83Name : MacroGenics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $115,763,120.00
EPSttm : -1.21
MacroGenics, Inc.
$1.83
2.23%$0.04Float Short %
6.62
Margin Of Safety %
Put/Call OI Ratio
0.09
EPS Next Q Diff
-0.92
EPS Last/This Y
0.19
EPS This/Next Y
-0.83
Price
1.84
Target Price
3.5
Analyst Recom
2.29
Performance Q
4.57
Relative Volume
0.81
Beta
1.51
Ticker: MGNX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-11 | MGNX | 1.413 | 0.07 | 0.00 | 5149 |
| 2025-12-12 | MGNX | 1.41 | 0.07 | 0.00 | 5152 |
| 2025-12-15 | MGNX | 1.375 | 0.07 | 999.99 | 5112 |
| 2025-12-16 | MGNX | 1.345 | 0.07 | 0.00 | 5112 |
| 2025-12-17 | MGNX | 1.605 | 0.07 | 0.03 | 5108 |
| 2025-12-18 | MGNX | 1.58 | 0.06 | 0.01 | 5564 |
| 2025-12-19 | MGNX | 1.51 | 0.06 | 0.00 | 5693 |
| 2025-12-22 | MGNX | 1.6 | 0.09 | 0.00 | 2876 |
| 2025-12-23 | MGNX | 1.605 | 0.09 | 0.00 | 2964 |
| 2025-12-26 | MGNX | 1.62 | 0.09 | 0.00 | 2970 |
| 2025-12-29 | MGNX | 1.61 | 0.09 | 0.44 | 3020 |
| 2025-12-30 | MGNX | 1.565 | 0.09 | 0.00 | 3037 |
| 2025-12-31 | MGNX | 1.62 | 0.09 | 0.00 | 3047 |
| 2026-01-02 | MGNX | 1.625 | 0.09 | 0.00 | 3154 |
| 2026-01-05 | MGNX | 1.725 | 0.09 | 0.00 | 3150 |
| 2026-01-06 | MGNX | 1.71 | 0.09 | 0.00 | 3172 |
| 2026-01-07 | MGNX | 1.82 | 0.09 | 0.01 | 3177 |
| 2026-01-08 | MGNX | 1.8 | 0.09 | 0.00 | 3226 |
| 2026-01-09 | MGNX | 1.83 | 0.09 | 0.00 | 3221 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-11 | MGNX | 1.42 | 97.6 | - | -0.89 |
| 2025-12-12 | MGNX | 1.40 | 97.6 | - | -0.89 |
| 2025-12-15 | MGNX | 1.37 | 97.6 | - | -0.89 |
| 2025-12-16 | MGNX | 1.37 | 97.6 | - | -0.89 |
| 2025-12-17 | MGNX | 1.61 | 97.6 | - | -0.89 |
| 2025-12-18 | MGNX | 1.57 | 97.6 | - | -0.89 |
| 2025-12-19 | MGNX | 1.50 | 97.6 | - | -0.89 |
| 2025-12-22 | MGNX | 1.62 | 97.6 | - | -0.89 |
| 2025-12-23 | MGNX | 1.61 | 97.6 | - | -0.89 |
| 2025-12-26 | MGNX | 1.62 | 97.6 | - | -0.89 |
| 2025-12-29 | MGNX | 1.61 | 97.6 | - | -0.89 |
| 2025-12-30 | MGNX | 1.57 | 97.6 | - | -0.89 |
| 2025-12-31 | MGNX | 1.62 | 97.6 | - | -0.89 |
| 2026-01-02 | MGNX | 1.62 | 97.6 | - | -0.89 |
| 2026-01-05 | MGNX | 1.72 | 97.6 | - | -0.89 |
| 2026-01-06 | MGNX | 1.71 | 97.6 | - | -0.89 |
| 2026-01-07 | MGNX | 1.81 | 97.6 | - | -0.89 |
| 2026-01-08 | MGNX | 1.79 | 97.6 | - | -0.89 |
| 2026-01-09 | MGNX | 1.84 | 97.6 | - | -0.89 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-11 | MGNX | 2.00 | -3.64 | 6.20 |
| 2025-12-12 | MGNX | 2.00 | -3.64 | 6.20 |
| 2025-12-15 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-16 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-17 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-18 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-19 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-22 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-23 | MGNX | 2.00 | -3.66 | 6.20 |
| 2025-12-26 | MGNX | 2.00 | -3.66 | 6.62 |
| 2025-12-29 | MGNX | 2.00 | -3.66 | 6.62 |
| 2025-12-30 | MGNX | 2.00 | -3.66 | 6.62 |
| 2025-12-31 | MGNX | 2.00 | -3.66 | 6.62 |
| 2026-01-02 | MGNX | 2.00 | -3.66 | 6.62 |
| 2026-01-05 | MGNX | 2.00 | -3.66 | 6.62 |
| 2026-01-06 | MGNX | 2.00 | -3.66 | 6.62 |
| 2026-01-07 | MGNX | 2.00 | -3.66 | 6.62 |
| 2026-01-08 | MGNX | 2.00 | -3.66 | 6.62 |
| 2026-01-09 | MGNX | 2.00 | -3.66 | 6.62 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.27
Avg. EPS Est. Current Quarter
-0.02
Avg. EPS Est. Next Quarter
-0.66
Insider Transactions
2
Institutional Transactions
-3.66
Beta
1.51
Average Sales Estimate Current Quarter
27
Average Sales Estimate Next Quarter
9
Fair Value
Quality Score
35
Growth Score
24
Sentiment Score
51
Actual DrawDown %
95
Max Drawdown 5-Year %
-97
Target Price
3.5
P/E
Forward P/E
PEG
P/S
0.91
P/B
1.73
P/Free Cash Flow
EPS
-1.21
Average EPS Est. Cur. Y
-0.89
EPS Next Y. (Est.)
-1.72
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-59.46
Relative Volume
0.81
Return on Equity vs Sector %
-140.5
Return on Equity vs Industry %
-125.2
EPS 1 7Days Diff
1.3
EPS 1 30Days Diff
0.83
EBIT Estimation
MacroGenics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 341
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading